Literature DB >> 1902397

Cytotoxic and noncytotoxic mechanisms involved in the in vitro anti-leukaemia effects of T cell clones established from a chronic myelogenous leukaemia patient during treatment in vivo with interferon alpha.

G Pawelec1, M Reutter, M Owsianowsky, A Rehbein, F W Busch.   

Abstract

T cell clones derived from a chronic myelogenous leukaemia (CML) patient during interferon alpha (IFN alpha, Wellferon) biotherapy preferentially lysed autologous rather than allogeneic CML target cells in an apparently MHC-unrestricted fashion, but also lysed bone marrow cells from certain normal donors regardless of whether or not they shared HLA antigens with the patient. Although T cell clones inhibited both CML and normal bone marrow in the colony-forming assay, they blocked proliferation of CML cells more efficiently than bone marrow cells. This inhibitory effect was mediated at least in part by the tumour necrosis factor alpha (TNF alpha) and IFN gamma secreted by the clones. Antisera to these cytokines partially prevented inhibition. Involvement of additional factors is also suggested in blocking CML cell proliferation because this was not 100% inhibited even by a combination of TNF alpha and IFN gamma. In addition, most clones failed strongly to block the proliferation of normal bone marrow cells, which were susceptible to inhibition by these cytokines.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1902397     DOI: 10.1007/bf01742529

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  24 in total

Review 1.  MHC-antigen interaction: what does the T cell receptor see?

Authors:  P Kourilsky; J M Claverie
Journal:  Adv Immunol       Date:  1989       Impact factor: 3.543

2.  Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients.

Authors:  S A Rosenberg; M T Lotze; J C Yang; P M Aebersold; W M Linehan; C A Seipp; D E White
Journal:  Ann Surg       Date:  1989-10       Impact factor: 12.969

3.  Serum-free medium for generation and propagation of functional human cytotoxic and helper T cell clones.

Authors:  H Yssel; J E De Vries; M Koken; W Van Blitterswijk; H Spits
Journal:  J Immunol Methods       Date:  1984-08-03       Impact factor: 2.303

4.  Specific, major histocompatibility complex-unrestricted recognition of tumor-associated mucins by human cytotoxic T cells.

Authors:  D L Barnd; M S Lan; R S Metzgar; O J Finn
Journal:  Proc Natl Acad Sci U S A       Date:  1989-09       Impact factor: 11.205

5.  Acute leukaemia in bcr/abl transgenic mice.

Authors:  N Heisterkamp; G Jenster; J ten Hoeve; D Zovich; P K Pattengale; J Groffen
Journal:  Nature       Date:  1990-03-15       Impact factor: 49.962

6.  Specific recognition of human leukemic cells by allogeneic T cells: II. Evidence for HLA-D restricted determinants on leukemic cells that are crossreactive with determinants present on unrelated nonleukemic cells.

Authors:  J A Sosman; K R Oettel; S D Smith; J A Hank; P Fisch; P M Sondel
Journal:  Blood       Date:  1990-05-15       Impact factor: 22.113

7.  Antitumor activity in vitro in chronic myelogenous leukaemia revealed after treating peripheral cells with cytosine arabinoside.

Authors:  G Pawelec; H Schmidt; A Rehbein; F Busch
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

8.  Autologous responses to human leukaemic cells in mixed leucocyte culture.

Authors:  L K Ashman; D E O'Keefe; C A Juttner; I R Toogood; M S Rice
Journal:  Cancer Immunol Immunother       Date:  1986       Impact factor: 6.968

9.  A large fraction of human peripheral blood gamma/delta + T cells is activated by Mycobacterium tuberculosis but not by its 65-kD heat shock protein.

Authors:  D Kabelitz; A Bender; S Schondelmaier; B Schoel; S H Kaufmann
Journal:  J Exp Med       Date:  1990-03-01       Impact factor: 14.307

10.  Antibody recognition of the tumor-specific bcr-abl joining region in chronic myeloid leukemia.

Authors:  J van Denderen; A Hermans; T Meeuwsen; C Troelstra; N Zegers; W Boersma; G Grosveld; W van Ewijk
Journal:  J Exp Med       Date:  1989-01-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.